미국의 소생대동맥혈관내풍선폐쇄술(REBOA) 시장 규모, 점유율, 동향 분석 : 최종 용도별, 부문별 예측(2025-2030년)

U.S. REBOA Market Size & Trends:

The U.S. resuscitative endovascular balloon occlusion of the aorta market size was valued at USD 7.2 million in 2024 and is projected to grow at a CAGR of 23.6% from 2025 to 2030. Key players such as Prytime Medical and Emergency Scientific, LLC drive REBOA device innovation in the U.S. through strategic collaborations, mergers, and acquisitions. Products like the Landmark REBOA Catheter convenience kit enhance procedural efficiency, while recent FDA approvals boost market growth. These advancements improve accessibility and effectiveness, expanding the market presence of resuscitative endovascular balloon occlusion of the aorta (REBOA) devices.

The growing number of traumatic injuries from road accidents, falls, and violence is a key factor fueling the U.S. REBOA market. This surge in critical cases increases the demand for effective emergency interventions such as REBOA. As a result, advancements and adoption of these life-saving devices continue to expand. According to the U.S. Bureau of Labor Statistics (BLS), in 2022, there were 5,486 fatal work injuries in the United States, marking a 5.7% increase from 2021. Transportation incidents were the leading cause, accounting for 37.7% of these fatalities. In 2023, the number of fatal work injuries decreased by 3.7% to 5,283, with transportation incidents remaining the most frequent cause, comprising 36.8% of fatalities.

Advancements in medical technology have greatly improved the safety and effectiveness of REBOA procedures. Innovations such as enhanced balloon designs, advanced catheter systems, and improved imaging allow for more precise placement and monitoring. These improvements lead to better patient outcomes and increased adoption of REBOA in trauma care. For instance, in June 2024, Utah-based Emergency Scientific announced the first use of its Landmark REBOA catheter after receiving FDA 510(k) clearance. The device is designed for temporary occlusion of large vessels to control emergency hemorrhages. Its advanced design improves occlusion precision while reducing complications compared to traditional methods.

Increasing healthcare spending is fueling the expansion of the U.S. REBOA industry. Higher investments in advanced medical technologies and trauma care are boosting the adoption of REBOA devices. This growth supports better emergency interventions and improved patient outcomes. According to the Centers for Medicare & Medicaid Services, in 2023, healthcare spending in the U.S. reached USD 4.9 trillion, marking a 7.5% increase, up from 4.6% in 2022. Medicare and private health insurance spending grew faster than in 2022. In 2023, the health sector accounted for 17.6% of the economy, comparable to 17.4% in 2022, but this figure is lower than the shares recorded in 2020 and 2021 at the height of the COVID-19 pandemic.

U.S. Resuscitative Endovascular Balloon Occlusion Of The Aorta Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. resuscitative endovascular balloon occlusion of the aorta market report based on end use:

• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Aortic Occlusion
• Cardiac Arrest
• Tactical Combat Casualty Care

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. End use
  • 1.2.2. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Legal landscape
    • 3.3.2.6. Environmental landscape

Chapter 4. U.S. Resuscitative Endovascular Balloon Occlusion of the Aorta Market: End Use Estimates & Trend Analysis

• 4.1. End Use Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. resuscitative endovascular balloon occlusion of the aorta market By End Use Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Aortic Occlusion
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cardiac Arrest
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Tactical Combat Casualty Care
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Company/Competition Categorization
• 5.2. Vendor Landscape
  • 5.2.1. Key company heat map analysis, 2024
• 5.3. Company Profiles
  • 5.3.1. Prytime Medical Devices, Inc
    • 5.3.1.1. Company overview
    • 5.3.1.2. Financial performance
    • 5.3.1.3. Product benchmarking
    • 5.3.1.4. Strategic initiatives
  • 5.3.2. Emergency Scientific, LLC
    • 5.3.2.1. Company overview
    • 5.3.2.2. Financial performance
    • 5.3.2.3. Product benchmarking
    • 5.3.2.4. Strategic initiatives
  • 5.3.3. Qx Medical
    • 5.3.3.1. Company overview
    • 5.3.3.2. Financial performance
    • 5.3.3.3. Product benchmarking
    • 5.3.3.4. Strategic initiatives
  • 5.3.4. Front Line Medical Technologies
    • 5.3.4.1. Company overview
    • 5.3.4.2. Financial performance
    • 5.3.4.3. Product benchmarking
    • 5.3.4.4. Strategic initiatives